Regen BioPharma (RGBPP) Enterprise Value (2016 - 2025)
Regen BioPharma (RGBPP) has disclosed Enterprise Value for 11 consecutive years, with -$4578.0 as the latest value for Q4 2025.
- On a quarterly basis, Enterprise Value rose 74.38% to -$4578.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$4578.0, a 74.38% increase, with the full-year FY2025 number at -$69555.0, down 864.57% from a year prior.
- Enterprise Value was -$4578.0 for Q4 2025 at Regen BioPharma, up from -$69555.0 in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$692.0 in Q2 2023 to a low of -$727162.0 in Q3 2021.
- A 5-year average of -$121094.7 and a median of -$69555.0 in 2025 define the central range for Enterprise Value.
- Peak YoY movement for Enterprise Value: skyrocketed 99.38% in 2023, then tumbled 8837.57% in 2024.
- Regen BioPharma's Enterprise Value stood at -$353492.0 in 2021, then surged by 88.47% to -$40741.0 in 2022, then plummeted by 205.58% to -$124497.0 in 2023, then soared by 85.65% to -$17868.0 in 2024, then skyrocketed by 74.38% to -$4578.0 in 2025.
- Per Business Quant, the three most recent readings for RGBPP's Enterprise Value are -$4578.0 (Q4 2025), -$69555.0 (Q3 2025), and -$1761.0 (Q2 2025).